Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165864 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPK1CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL18415547 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPK1TSHRSMN1; SMN2MAPT | |
| SCHEMBL257873 | 0.81 | ALDH1A1 (0.69) | ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19032000 | 0.81 | ALDH1A1 (0.69) | ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14743537 | 0.81 | ALDH1A1 (0.69) | ALDH1A1MAPK1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL15458939 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MAPK1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL921629 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MAPK1MAOBMAOANPC1 | |
| SCHEMBL921951 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPK1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL7285919 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPK1CYP19A1CYP3A4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6158469 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPK1MAOBMAOANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-0353032-B1 | 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Sankyo Company Limited (JP) | 1992-02-26 | — | — | EP | disclosed |
| US-5002942-A | Calcium channel blockers for cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1991-03-26 | — | — | US | disclosed |
| EP-0353032-A1 | 1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | ALDH1A1 1063/4885MAPK1 3702/4885CYP19A1 4357/4885 |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CYP19A1 3496/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CYP19A1 3496/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CYP19A1 3496/4885 |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX1, P2RX4, P2RX2 | ALDH1A1 531/4885MAPK1 3251/4885CYP19A1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.